Facing Up To A Patent Cliff: Indivior Plans For Loss of Suboxone Film Exclusivity

19 Feb 2019

• By John Davis

With sales of its largest-selling product under threat from generic competition, a couple of new products and cost cuts are put forward to reinvigorate Indivior, a leader in addiction therapies.

Indivior PLC’s contingency planning for the potential loss of US market exclusivity for its largest-selling product, sublingual Suboxone Film (buprenorphine/naloxone), includes conserving cash while supporting the commercialization of two newer products, the possible introduction of an authorized generic through its partner, Sandoz International GMBH, and reducing costs.

“The over-riding objectives of the contingency plan are to provide for the commercial success of Sublocade (buprenorphine) extended-release subcutaneous monthly injections, and Perseris (risperidone) monthly-long acting injections, while ensuring a minimum cash balance of $250m to remain in compliance with

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: US FDA Delay Sends Biohaven Shares Down

16 May 2025

• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Multiple Launches Help Lilly’s Japan Growth

15 May 2025

• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Lundbeck Lifted By Leap In Migraine Therapy Sales

14 May 2025

• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

13 May 2025

• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.